ASX:DXB
Dimerix Limited Stock Company Profile
$0.470
+0 (+0%)
At Close: Jul 04, 2024
Information
425 Smith Street
Fitzroy VIC 3065
61 3 0081 3321
dimerix.com
Industry: Biotechnology
Sector: Healthcare
Description
Dimerix Limited, a clinical-stage biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. The company develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; and DMX-700 that is in pre-clinical development for chronic obstructive pulmonary disease. The company was founded in 2004 and is headquartered in Fitzroy, Australia.
